KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) insider Edward P. Feener sold 8,088 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.76, for a total value of $95,114.88. Following the sale, the insider now directly owns 72,858 shares in […]
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its.
AJOVista LLC Acquires Shares of 4,920 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.